Clinical Trial Update: 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates 10-day decitabine, fludarabine, and 2 Gy total body irradiation as a conditioning regimen for poor-risk AML patients in first…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Fludarabine (Fludarabine)
• total body irradiation (2 Gy) (2 Gy total body irradiation)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: COMPLETED